MYCR: Clustered Downgrades And Extended Deliveries Will Pressure Near Term Upside

The updated analyst price target for Mycronic has shifted from SEK 226.50 to SEK 260.25. Analysts cite changes in growth expectations and valuation assumptions, even as several firms have recently turned more cautious on the stock.

Analyst Commentary

Recent research on Mycronic reflects a more cautious tone, with several bearish analysts revisiting their assumptions on growth and valuation. The updated price target points to a recalibration rather than a clear consensus shift in one direction.

Bullish Takeaways

The higher price target to SEK 260.25 suggests some bullish analysts still see room for upside based on their growth frameworks, even as more conservative peers turn cautious.
Supportive views often focus on Mycronic’s ability to execute on its existing order book and product pipeline, which they see as a base case for justifying the current valuation range.
Bullish analysts tend to argue that the stock’s long term exposure to electronics production and related capital spending remains attractive for patient investors, assuming steady execution.
Some see the recent moderation in sentiment as already reflected in current pricing, which they think limits the downside implied by the more bearish calls.

Bearish Takeaways

Bearish analysts have downgraded the stock, signalling concern that earlier growth assumptions may have been too optimistic relative to the company’s current visibility.
They highlight the risk that any slowdown in order intake or project timing could pressure near term earnings, which in turn could challenge the higher end of valuation ranges used in prior models.
There is also caution that the stock’s current P/E and related multiples may leave limited margin for error if execution falls short of existing expectations.
These analysts stress that with several downgrades clustered together, investor sentiment may remain fragile, especially if upcoming updates do not clearly support the updated target assumptions.

What's in the News

Mycronic raised its 2026 net sales guidance, with the Board adjusting its view from SEK 8.25b to SEK 8.75b for the period (Corporate Guidance, Key Developments).
The company received an order for a customized SLX mask writer from a new customer, valued in the range of US$27m to US$30m, with delivery planned for 2028 (Client Announcements, Key Developments).
Mycronic booked an order for an SLX mask writer from an existing customer in Asia, valued in the range of US$5m to US$7m, with delivery planned for the second quarter of 2027 (Client Announcements, Key Developments).

Valuation Changes

Fair Value: SEK 226.50 updated to SEK 260.25, reflecting a higher central valuation point in the latest models.
Discount Rate: 6.59% updated to 6.92%, implying a slightly higher assumed required return on Mycronic’s cash flows.
Revenue Growth: 6.57% updated to 10.68%, indicating a higher assumed long term SEK revenue growth rate in the revised estimates.
Net Profit Margin: 21.00% updated to 18.12%, pointing to a more conservative view on future profitability levels.
Future P/E: 26.50x updated to 30.43x, suggesting that the refreshed valuation framework uses a higher earnings multiple for forward years.

3 views

Key Takeaways

Mycronic's acquisitions and new technology launches are bolstering revenue and market position, particularly in the Global Technologies and display industries.
Strategic geographic expansion and increased R&D investments indicate potential for long-term revenue growth and market diversification.
The combination of tariffs, demand weakness, and currency fluctuations is leading to declining revenues and earnings instability in Mycronic's High Flex division.

Catalysts

About Mycronic

Develops, manufactures, and sells production equipment for electronics industry in Sweden, rest of Europe, the United States, other Americas, China, South Korea, rest of Asia, and internationally.What are the underlying business or industry changes driving this perspective?

Mycronic's recent acquisitions, such as Hprobe and RoBAT, are expected to expand its offerings in the Global Technologies division with unique technologies for testing MRAM and PCBs, potentially leading to increased revenue and strengthened market position.
The successful launch of the Prexision 8000 Evo, a high-end machine for mask writing in the display industry, confirms alignment with industry needs, and its reception may drive future order volumes, positively impacting revenue and earnings.
Strong growth in the company's High Volume division, particularly in the Chinese domestic market, suggests potential for increased sales and revenue growth, supported by a robust order backlog.
Continued expansion into new regions, like Southeast Asia, for High Volume production indicates strategic geographic diversification, which may enhance revenue stability and long-term growth prospects.
Increased R&D investments in Pattern Generators, with a focus on new product development and market opportunities such as inspection and quality control, could support long-term revenue growth and competitive positioning.

Mycronic Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Mycronic's revenue will grow by 10.7% annually over the next 3 years.
Analysts assume that profit margins will shrink from 19.9% today to 18.1% in 3 years time.
Analysts expect earnings to reach SEK 2.0 billion (and earnings per share of SEK 11.03) by about May 2029, up from SEK 1.7 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 30.5x on those 2029 earnings, down from 35.0x today. This future PE is greater than the current PE for the GB Electronic industry at 27.8x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.92%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The impact of new tariffs in the U.S. has caused delays in deliveries within the High Flex division, negatively impacting quarterly earnings by SEK 15 million and potentially affecting future revenues due to hesitation in investments.
There is noted weakness in demand within the High Flex division, particularly in Europe, leading to a decrease in order intake by 12% and negatively impacting net sales and earnings.
The financial outlook is uncertain due to fluctuations in exchange rates and the potential indirect effects of tariffs, which could lead to lower projected sales and impact both revenue and net margins.
Uncertainty in the investment climate and potential hesitation to invest due to market conditions and currency fluctuations could lead to volatility in order intake and revenues, especially in divisions with shorter lead times like High Flex.
Dependency on a limited number of customers in some divisions, such as Die Bonding in the Global Technologies division, can lead to fluctuating order intake, impacting revenue stability and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of SEK260.25 for Mycronic based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of SEK315.0, and the most bearish reporting a price target of just SEK176.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be SEK11.3 billion, earnings will come to SEK2.0 billion, and it would be trading on a PE ratio of 30.5x, assuming you use a discount rate of 6.9%.
Given the current share price of SEK297.0, the analyst price target of SEK260.25 is 14.1% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Mycronic?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Upcoming Orders and Expansion Will Drive Global Technology Reach Forward